Role of superoxide in pulmonary hypertension and treatment with xanthine oxidase inhibition

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462357
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Anesthesiology
• Research Institution: Mie University
• Principal Investigator: Yokochi Ayumu 三重大学, 医学部附属病院, 講師 (60359768)
• Research Collaborator: MARUYAMA Junko
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 肺高血圧 / スーパーオキシド / キサンチンオキシダーゼ / フェブキソスタット

Outline of Final Research Achievements

Febuxostat, being a novel xanthine oxidase inhibitor, is apparently having a beneficial role in improving the endothelial dysfunction. The purpose of the present study was to investigate whether febuxostat (FBS) prevents the development of pulmonary hypertension (PH) in both monocrotaline (MCT)-injected rats and in rats exposed to chronic hypobaric hypoxia (CH)(380 mm Hg, 10% oxygen).
The mean pulmonary artery pressure (mPAP), right ventricular hypertrophy (RVH), percentages of muscularized peripheral arteries (%muscularization), and medial wall thickness of small muscular arteries (%MWT) were measured. MCT increased mPAP, RVH, %muscularization, and %MWT.CH increased mPAP, RVH, %muscularization, and %MWT.FBS treatment did not significantly reduced mPAP, RVH, %muscularization, and %MWT in both MCT-injected rats and in rats exposed to CH. FBS does not appear to prevent the development of pulmonary hypertension (PH) in both MCT-injected rats and in rats exposed to CH.

Free Research Field

医学